NEWS

Coompany
thumb
2018 / 08 / 09

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

<Abstract> Although programmed death-ligand 1–programmed death 1 (PD-L1–PD-1) inhibitors are broadly efficacious, improved outcomes have been observed in patients with high PD-L1 expression or high tumor mutational burden (TMB). PD-L1...

thumb
2018 / 07 / 31

Pathogenic Germline Variants in 10,389 Adult Cancers

<Abstract> We conducted the largest investigation of predisposition variants in cancer to date, discovering 853 pathogenic or likely pathogenic variants in 8% of 10,389 cases from 33 cancer types. Twenty-one genes showed single or cro...

thumb
2018 / 07 / 31

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer

<Abstract> Recent advances in DNA profiling techniques have enabled sensitive detection of tumor-associated genomic aberrations in peripheral blood. This type of minimally-invasive molecular interrogation has the potential to guide su...

thumb
2018 / 05 / 25

Femtopath citation update: Journal of Thoracic Oncology, Volume 13, Issue 6, 2018.

<Title> Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non–Small Cell Lung Cancer with Multiple Driver Mutations     <Abstract> Lung cancer is the leading cause of cancer deaths worldwide and i...

thumb
2018 / 05 / 19

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

<Check Poziotinib Panel Products>   <Title> Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer <Abstract> Although most activating mutations of epider...

thumb
2018 / 05 / 15

Third generation EGFR TKIs: current data and future directions

<check Femtopath C797 mutation kit>   <Abstract> Acquired T790M mutation is the commonest cause of resistance for advanced non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had p...

thumb
2018 / 03 / 26

Pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection

<Title> Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial <Abstract> Mutation detection accuracy has been described extensively; however, it is su...

thumb
2018 / 01 / 04

OncoKB: A Precision Oncology Knowledge Base

<Purpose> With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a ...

thumb
2018 / 01 / 04

The cutoff limit of reference intervals for mutant KRAS was determined to be ~ 0.09% based on samples from healthy individuals

 <Title> An improved digital polymerase chain reaction protocol to capture low‐copy KRAS mutations in plasma cell‐free DNA by resolving ‘subsampling’ issues   <Abstract> Genetic alterations responsible for the initiation of...

thumb
2017 / 11 / 12

Small Cell Carcinoma of the Urinary Bladder and Implications for Diagnosis, Prognosis, and Treatment

    <Abstract> Importance  Small cell carcinoma of the urinary bladder is a rare and aggressive neuroendocrine tumor of the urinary bladder. Although research has been performed since the first case was reported in 1981, mos...

thumb
2017 / 09 / 03

大腸瘜肉基因檢測評估說明

目前大腸癌檢測最普遍的還是用內視鏡的方式進行大腸息肉檢測,為了彌補現有病理學上面的缺口(包含:一些難辨識組織型態以及靈敏度不佳蛋白質標記),針對高風險的族群(包含有家族病史/多個或是較大息肉/年長者/或有相關慢性及疾病等等)提供息肉基因檢測服務。FemtoPath mutation screen kits 利用sanger sequencing的方式,針對檢體中基因序列直接判讀,直接看到突變點位以及突變型態,此外也可針對hot spot的位置,偵測已知以及未知的突變位點(Pa...

thumb
2017 / 08 / 21

A pathology atlas of the human cancer transcriptome

<Abstract> Cancer is one of the leading causes of death, and there is great interest in understanding the underlying molecular mechanisms involved in the pathogenesis and progression of individual tumors. We used systems-level approac...

thumb
2017 / 08 / 18

Direct detection of early-stage cancers using circulating tumor DNA

<Abstract> Early detection and intervention are likely to be the most effective means for reducing morbidity and mortality of human cancer. However, development of methods for noninvasive detection of early-stage tumors has remained a...

thumb
2017 / 08 / 10

Clarity™ digital PCR system: a novel platform for absolute quantification of nucleic acids

<Abstract> In recent years, digital polymerase chain reaction (dPCR) has gained recognition in biomedical research as it provides a platform for precise and accurate quantification of nucleic acids without the need for a standard curv...

thumb
2017 / 08 / 09

Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Check our TP53 mutation kit here   <Title> Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients <Background> During posttreatment surveillance of head and ...

thumb
2017 / 07 / 24

Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

<Title> Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. <Abstract> DNA mismatch repair (MMR) pro...

thumb
2017 / 05 / 24

Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing

<Abstract> Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are effective against lung adenocarcinomas harboring epidermal growth factor receptor (EGFR) mutations. However, cancer cells can develop resistance to these...

thumb
2017 / 05 / 15

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

<Abstract> This guideline presents recommendations for the management of patients with hereditary gastrointestinal cancer syndromes. The initial assessment is the collection of a family history of cancers and premalignant gastrointest...

thumb
2017 / 05 / 15

British Society of Gastroenterology position statement on serrated polyps in the colon and rectum

<Abstract> Serrated polyps have been recognised in the last decade as important premalignant lesions accounting for between 15% and 30% of colorectal cancers. There is therefore a clinical need for guidance on how to manage these lesi...

thumb
2017 / 05 / 04

A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome

<Title> A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome   <Abstract> To determine the correlation between BRAF genotype and MLH1 promoter methylation in a screeni...

thumb
2017 / 04 / 29

Rydapt® (midostaurin, formerly PKC412), FDA approves new combination treatment for acute myeloid leukemia.

<FDA Release> The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3, in combina...

thumb
2017 / 03 / 02

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

For third-generation inhibitor, limit of detection of EGFR T790M mutation must be reaching 0.1 to 0.01% . Femtopath now offer you more affordable and high sensitivity T790M mutation kit, especially  in plasma cfDNA.       &nb...

thumb
2017 / 02 / 02

Study provides link between common mutations in blood cells of older adults and atherosclerosis

<Title> Study provides link between common mutations in blood cells of older adults and atherosclerosis <Abstract> A new study provides some of the first links between relatively common mutations in the blood cells of elderly hu...

thumb
2016 / 12 / 30

Femtopath Kras mutation screen kit citation-2

<Journal> Human Genomics (2016) 10:40; (SCI Impact factor=3.385) <Title> The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma. <Abstract> Jayson GC et al. remarked in Lancet that nearly 100% of...

thumb
2016 / 11 / 02

白血病之中西醫對話論壇_中醫四診與致癌基因篩檢

◎簡介: 白血病位居癌症發生率第十名,事先沒有任何預兆,一旦發病便來勢洶 洶,沒有早晚期之分,也無法開刀治療。白血病前期的治療包含支持性療法, 以及低或高強度的化學治療。當發展為白血病時,只能採用高強度化療合併骨髓移植,然而預後及臨床反應均不是很好。近期白血病的治療亦有一些標靶藥物的設計,某些藥物具有明顯的生命延長效果,然而大多需要終生服藥。意義不明的克隆性造血(clonal hematopoiesis of indeterminatepotential,CHIP)是指骨髓或...

thumb
2016 / 11 / 01

Kras mutation screen kit citation

<Title> Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms <Abstract> Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess ...

thumb
2016 / 10 / 29

Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline

<Primary Screening> Human papillomavirus (HPV) DNA testing is recommended in all resource settings. Visual inspection with acetic acid may be used in basic settings. The recommended age ranges and frequencies in each setting are as fo...

thumb
2016 / 03 / 31

Circulating mutant DNA to assess tumor dynamics

<Title> Circulating mutant DNA to assess tumor dynamics   <Abstract> The measurement of circulating nucleic acids has transformed the management of chronic viral infections such as HIV. The development of analogous markers ...

thumb
2016 / 03 / 14

GenonFire training video update

For inside training use  

thumb
2016 / 02 / 25

A New RAS G12D Specific Antibody for Immunohistochemical FFPE Application

<Ttile> A New RAS G12D Specific Antibody for Immunohistochemical FFPE Application <Event> Femtopath/Genetex will attend 2016 AACR on April in New Orlean <Topic> Femtopath/Genetex show a specific RAS G12D antibody, which de...

thumb
2016 / 02 / 17

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy

<title> Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline <abstract> Purpose To provide recomme...

thumb
2016 / 02 / 17

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

<title> Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer <abstract> Purpose BRAF V600 Emutationisseenin 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated...

thumb
2016 / 02 / 05

A Total Solution From Liquid Based Cytology To Molecular Diagnosis

HongJing Bio (Femtopath) expands its commitment to provide a total solution in providing a more efficient procedure from liquid based cytology to molecular diagnosis. BRAF mutation detection in thyroid cytology specimens requires not only c...

thumb
2015 / 12 / 31

Driver and Passenger Mutations in Cancer

<Title> Driver and Passenger Mutations in Cancer <Author> Julia R. Pon and Marco A. Marra <Abstract> Next-generation sequencing has allowed identification of millions of somatic mutations and epigenetic changes in cancer ce...

thumb
2015 / 12 / 17

Kras G12D mutation antibody

Kras G12D mutation was been validated by Femtopath Kras mutation IHC method: Roche Ventena, Optiview detection kit,  Ab titration:1000X.

thumb
2015 / 10 / 22

Approach 0.5% detection sensitivity with 200 reading depth

<Material and Method> 1. Femtopath enrichment method 2. Specific adaptor 3. Illumina NGS system <Data summary> 1. Raw data from “FemtoPath mutation enrichment assays” plus “Illumina MiSeq” can significantly locate mutations from...

thumb
2015 / 10 / 15

EGFR positive rate(78.08%) is higher than Brand C (72.6%)

<Title> 高敏感度核酸定序分子診斷技術 <Author> 黃志凱  馬偕紀念醫院病理科 <Abstract> 大約35%非小細胞肺癌(non-small cell lung cancer;NSCLC)的患者具有 EGFR基因突變,並對EGFR 抑制劑,如 Tarceva具有高度的反應。醫生需要根據患者的分子檢測結果決定適合患者的治療方式。現今已有許多分子生物技術,如  HRM (HighResolution  Melt) analys...

thumb
2015 / 10 / 14

ASCO臨床腫瘤年會發表臨床試驗論文對大腸癌標靶治療 再次要求All-Ras的檢驗應該要陰性

<Title> Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor ReceptorMonoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion ...

thumb
2015 / 09 / 29

醫材申請臨床試驗是提升產品系統與公司品牌的價值 (Design Control: 確認未來與現在的需求)

食藥署自102年起依據國內醫療器材產業發展趨勢,優先培育來自國內各大醫學中心相關科別(骨科、檢驗科、整形外科、心血管科、婦產科)之臨床試驗種子醫師,赴海外實地參與先進國家(美國、日本)之臨床試驗。期能經由早期介入高階醫療器材臨床試驗規劃及執行階段,通盤理解醫療器臨床試驗核心價值,並藉由相關產、學、研、醫界互動之過程,建立良好溝通橋樑,深化瞭解醫療器材臨床試驗產業上的創新價值,擴展國內醫療器材臨床試驗視野及強化跨國高階醫療器材研發合作量能,進而提升醫療器材產業全球化競爭力。  ...

thumb
2015 / 09 / 26

精準醫療與標靶治療與免疫治療系列(PD-1/PDL-1)

thumb
2015 / 09 / 03

Femtopath citation updated_ASCO 2013(2/2)

<Title> Using low sensitivity of direct sequencing to detect K-ras mutations? A new method for improving diagnostic accuracy.   <Author> Chi-Kuan Chen; Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan  ...

thumb
2015 / 09 / 03

Femtopath citation updated_ASCO 2013(1/2)

<Title> Identification of real-time PCR-negative EGFR mutations by direct sequencing test <Author> Tao-Yeuan Wang, Chi-Kuan Chen; Department of Pathology, Mackay Memorial Hospital, Taipei, Taiwan <Abstract> Background: Hig...

thumb
2015 / 08 / 31

Femtopath submit a poster to APIAP, Korea, 2013.

We are honored to be able to participate on the 8th Asia Pacific IAP Congress on Busan, Korea. Sharing our technology on how we can improve the accuracy and sensitivity of cancer mutation detection. By using Femtopath mutation enrichment ki...

thumb
2015 / 07 / 29

Femtopath from Sanger to NGS-Medical

Femtopath from Sanger to NGS  

loading